# US 8,278,268 B2 · Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,268 B2
- Document ID: US8278268B2
- Status: Granted
- Kind: B2
- Application number: 11/923,120
- Filed: 2007-10-24
- Published: 2008-04-24
- Granted: 2012-10-02
- Earliest claimed: 2001-04-04
- Assignees: Ortho-McNeil Pharmaceutical, Inc.
- Inventors: Jacqueline C. Bussolari; Xiaoli Chen; Bruce R. Conway; Keith T. Demarest; Hamish N. M. Ross; Rafael Severino
- Web page: https://patentgrep.com/patent/US8278268B2

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/31: containing nitrogen
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

## Claims

### Claim 1

A method for treating diabetes or Syndrome X in a subject, said method comprising
(a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; and
(b) administering to said subject a jointly effective amount of a PPAR modulator,
said co-administration being in any order and the combined jointly effective amounts providing the desired therapeutic effect and a reduction in a side effect associated with the PPAR modulator administered alone.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PPAR modulator is a PPARγ agonist.

### Claim 3 (depends on 1)

The method of claim 1, wherein the PPAR modulator is a thiazolidinedione or a non-thiazolidinedione insulin sensitizer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the PPAR modulator is selected from
(a) rosiglitazone;
(b) pioglitazone;
(c) troglitazone;
(d) isaglitazone;
(e) 5-BTZD;
(f) JT-501;
(g) KRP-297;
(h) Farglitazar;
(i) Risarestat;
(j) YM 440;
(k) NN 2344;
(I) NN 622;
(m) AR-H039242;
(n) Fenofibrate; and
(o) bexarotene.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein the diabetes is IDDM.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2, wherein the diabetes is NIDDM.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, further comprising administering to said subject a jointly effective amount of a third antidiabetic agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the third antidiabetic agent is selected from
(aa) insulins,
(bb) insulin analogues;
(cc) insulin secretion modulators, and
(dd) insulin secretagogues.

### Claim 9 (depends on 8)

The method of claim 8, wherein the diabetes is IDDM.

### Claim 10 (depends on 1, 2)

The method of claim 1 or 2, wherein the glucose reabsorption inhibitor is an SGLT inhibitor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the glucose reabsorption inhibitor is an SGLT1 inhibitor.

### Claim 12 (depends on 10)

The method of claim 10, wherein the glucose reabsorption inhibitor is an SGLT2 inhibitor.

### Claim 13 (depends on 1)

The method of claim 1, wherein the glucose reabsorption inhibitor is a compound of Formula (V)
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
Ar is aryl or heteroaryl;
OX is an optionally protected hydroxy group;
Y is hydrogen or alkyl; and
Z is glucopyranosyl wherein one or more hydroxy groups thereof may optionally be substituted with one or more groups selected from α-D-glucopyranosyl, alkanoyl, alkoxycarbonyl, and substituted alkyl.

### Claim 14 (depends on 13)

The method of claim 13, wherein the glucose reabsorption inhibitor is a compound of Formula (IV)
wherein Ar is an aryl group, R1 is hydrogen atom or an acyl group, R2 is hydrogen atom, an acyl group or α-D-glucopyranosyl group, or R1 and R2 may combine together to form a substituted methylene group, R3 and R4 are each hydrogen atom or an acyl group, and OR5 is a protected or unprotected hydroxy group or a lower alkoxy group.

### Claim 15 (depends on 13)

The method of claim 13, wherein the glucose reabsorption inhibitor is a compound of Formula (III)
wherein R′ is a lower alkanoyl group, and R″ is a hydrogen atom, or R′ is a hydrogen atom, and R″ is a lower alkoxycarbonyl group.

### Claim 16 (depends on 13)

The method of claim 13, wherein the glucose reabsorption inhibitor is a compound of Formula (II)
wherein X is an oxygen atom, a sulfur atom or a methylene group, OY is a protected or unprotected hydroxy group, Z is a β-D-glucopyranosyl group or 4-O-(α-D-glucopyranosyl)-β-D-glucopyranosyl group wherein one or more hydroxy groups of these groups may optionally be acylated, and the dotted line means the presence or absence of a double bond.

### Claim 17 (depends on 13)

The method of claim 13, wherein the glucose reabsorption inhibitor is a compound of Formula (I)
wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a β-D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected.

### Claim 18 (depends on 17)

The method of claim 17, wherein the glucose reabsorption inhibitor is T-1095 or T-1095A
with one or more hydroxyl or diol protecting groups, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein the glucose reabsorption inhibitor is T-1095 or T-1095A,
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 17)

The method of claim 17 wherein the glucose reabsorption inhibitor is T-1095 or T-1095A with one or more hydroxyl or diol protecting groups, or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The method of claim 20 wherein the glucose reabsorption inhibitor is T-1095.

### Claim 22 (depends on 20)

The method of claim 20 wherein the glucose reabsorption inhibitor is T-1095A.

### Claim 23 (depends on 20)

The method of claim 20, wherein the jointly effective amount of T-1095 or T-1095A is an amount sufficient to reduce the plasma glucose excursion following a meal.

### Claim 24

A method for treating diabetes, Syndrome X, or associated symptoms or complications thereof in a subject, said method comprising
(a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; and
(b) administering to said subject a jointly effective amount of a PPAR modulator,
said co-administration being in any order and the combined jointly effective amounts providing the desired therapeutic effect and a reduction in a side effect associated with the PPAR modulator administered alone; and wherein said diabetes, Syndrome X, or associated symptoms or complications thereof is selected from the group consisting of IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclorosis, polycystic ovary syndrome or polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.

### Claim 25 (depends on 24)

The method of claim 24, wherein the PPAR modulator is a PPARγ agonist.

### Claim 26 (depends on 24)

The method of claim 24, wherein the PPAR modulator is a thiazolidinedione or a non-thiazolidinedione insulin sensitizer.

### Claim 27 (depends on 24)

The method of claim 24, wherein the PPAR modulator is selected from
(a) rosiglitazone;
(b) pioglitazone;
(c) troglitazone; and
(d) isaglitazone.

### Claim 28 (depends on 1)

The method of claim 1, wherein the side effect is selected from the group consisting of fatty liver, increased liver weight, body weight gain, heart weight gain, edema, cardiac hypertrophy, hepatohypertrophy, hypoglycemia and hepatotoxicity or combination thereof.

### Claim 29 (depends on 24)

The method of claim 24, wherein the side effect is selected from the group consisting of fatty liver, increased liver weight, body weight gain, heart weight gain, edema, cardiac hypertrophy, hepatohypertrophy, hypoglycemia and hepatotoxicity or combination thereof.
